FDA Meeting: Clinical Accuracy Requirements for Point of Care Blood Glucose Meters

Arleen F. Pinkos, M.T., ASCP

L he Food and Drug Administration (FDA) has become increasingly concerned about the use of point of care blood glucose meters. A public meeting to discuss issues related to their use, hosted by FDA's Center for Device and Radiological Health, Office of In Vitro Diagnostic Device Evaluation, will take place on March 16 and 17, 2010. Goals of the meeting include: raising public awareness and obtaining public input about the accuracy and clinical use of blood glucose meters; sharing ideas on the challenges associated with their use; and working toward identifying solutions. The meeting will also include discussions about the liabilities that clinicians face in regards to their involvement with blood glucose meters.

The FDA would like to extend an invitation to the members of the Diabetes Technology Society. We are aware of the important work which your group has done in the area of glucose meters and believe your contributions will be significant and valuable.

NAME: Clinical Accuracy Requirements for Point of Care Blood Glucose Meters

DATE: March 16 and 17, 2010

TIME: 9:00 AM until 5:00 PM on March 16 and 9:00 AM until 3:40 PM EST on March 17

LOCATION: Hilton Washington DC, 620 Perry Pkwy, Gaithersburg, MD 20877

Details about the meeting including the agenda, Federal Register Notice and how to register can be found at: http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm187406.htm

Registration requests should be received by February 25, 2010. Registration is free and will be on a first-come, first-served basis. Early registration is recommended because seating is limited.

If you need additional information or have questions, please feel free to contact me at:

301-796-6152 or Arleen.Pinkos@FDA.HHS.gov

Author Affiliation: U.S. Food and Drug Administration, Center for Devices and Radiological Health, Office of In Vitro Diagnostic Device Evaluation and Safety, Silver Spring, Maryland

Keywords: accuracy, FDA, glucose, meters

Corresponding Author: Arleen F. Pinkos, M.T., ASCP, FDA/CDRH/Office of In Vitro Diagnostic Device Evaluation and Safety, 10903 New Hampshire Avenue, Building 66, Room 5618, Silver Spring, MD 20993; email address <u>Arleen.Pinkos@FDA.HHS.gov</u>